Biotech in Belgium: news and updates

News and Trends 1 Feb 2017

Young Belgian Biotech will tackle Fibrosis with a New Grant

Confo Therapeutics has received a €1.6M grant to support the discovery of drugs against fibrosis, one of the most deadly conditions in Western countries. Confo Therapeutics is a young biotech in Brussels developing a unique technology to target historically undruggable G protein-coupled receptors (GPCRs). The company just announced it received a €1.6M grant from Flanders Innovation & […]

February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Feb 2017

Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II

TiGenix has treated the first patient in a new early-stage clinical trial to test its candidate Cx611 as a treatment for sepsis in patients with pneumonia. TiGenix, based in Belgium, develops stem cell therapies derived from donors. This morning, the first patient was treated in a Phase Ib/IIa clinical trial for its candidate therapy Cx611 in […]

February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Jan 2017

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Ablynx has treated its first patient in a new trial targeting RSV infections, the main cause of children hospitalizations. Ablynx, one of the few European biotechs that made it into JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 07 at 3.46.36 PM e1481122126679

News and Trends 15 Dec 2016

UPDATE: European Stem Cell Therapy Pioneer goes for €34M IPO

TiGenix is entering the Nasdaq with an IPO aimed at funding clinical trials. Will this move allow the company to make it through clinical trials? TiGenix is a Belgian company behind ChondroCellect, the first cell therapy approved on the European market. The biotech has now announced a Nasdaq IPO that aims to raise €39.8M in order to fund […]

December 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Dec 2016

Galapagos gets another Milestone Payment from Gilead

Galapagos is starting a new PhaseIIb/III clinical trial for ulcerative colitis that has triggered a €9.4M milestone payment from Gilead. Can this partnership beat out its many competitors? Galapagos is one of the few billion-euro biotechs in Europe, boasting top-level partnerships with AbbVie for cystic fibrosis and MorphoSys for inflammatory diseases. The company now has news […]

December 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Nov 2016

One Step Closer to the First Triple Combination Therapy for Cystic Fibrosis

Galapagos and AbbVie are closer to launching a cystic fibrosis treatment that can outperform the current standards. However, gene therapy and CRISPR might end up taking over in the long term. Despite being abandoned by AbbVie in its rheumatoid arthritis program, Galapagos and the big US pharma expanded their cystic fibrosis partnership in May. The […]

November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Nov 2016

These Biotech Veterans have Launched a Startup to ‘Drug the Undruggable’

GPCRs have spelled “dead end” for many a biotech and academic endeavor. I sat down with Confo Therapeutics to hear about how they’re recruiting antibodies for a new onslaught. Despite their allure as the key to many indications, GPCRs are not a target for the faint of heart because they tend to move through a […]

November 23, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 21 Nov 2016

Celyad’s Autologous CAR-T Therapy enters Phase Ib

Celyad has received approval to start Phase Ib trials in Belgium with its autologous CAR-T therapy, which can target 80% of tumors. After a successful Phase I in leukemia and myeloma, Celyad is ready to start a Phase Ib trial for its autologous NKR-2 in 7 cancer indications, now including solid tumors. The new trial, aimed to examine different […]

November 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

liver anatomy organs Sebastian Kaulitzki fi

News and Trends 21 Nov 2016

“We are Pioneering Cell Therapy to Cure NASH and Fibrotic Disease”

Promethera is collecting cash to fuel its liver disease program that revolves around HepaStem. I sat down with the CEO to hear more about the link between the company’s seemingly diverse interests and future direction. Promethera is the new kid on Belgium’s biotech block in Louvain-la-Neuve, and it’s hatching plans to make a splash with an IPO next spring. […]

November 21, 2016 - 7 minutesmins - By Evelyn Warner

News and Trends 17 Nov 2016

UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy

UniQure just announced a new R&D plan designed to save up to €27M over the next two years. Will the new strategy be enough to pull it out of its down spiral? UniQure is a Dutch biotech famous for launching Glybera, the first commercial gene therapy worldwide. However, the huge price of the treatment has […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Nov 2016

This Company has developed a Personalized App to Fight Cancer

We say goodbye to the good weather in Spain and cross the Pyrenees to visit Charleroi, an industrial city south of Brussels. There, we find OncoDNA, a young company striving to change the oncology field using DNA. City: Charleroi, Belgium Founded: 2012 Employees: 11 – 50 Financial data: €7.7M raised in September to expand into the global market Mission: […]

November 4, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 1 Oct 2016

This Belgian Bioartist is deconstructing Chicken Evolution

Koen Vanmechelen is an artist that works in the intersection of art and research. His art focuses on exploring biocultural diversity… using chickens! Koen Vanmechelen‘s core artistic work is the Cosmopolitan Chicken Project (CCP), in which the artist cross-breeds chickens from all around the world. The aim: to create the ultimate chicken that will combine genes from […]

October 1, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us